Abstract Library

#2972 Characteristics and Management of Paragangliomas, 10 Years Experience

Introduction: Paraganglioma (PG) is a rare extra-adrenal neuroendocrine tumor, with common sites of presentation being abdomen, and head and neck region. The majority of PGs appear to be sporadic. However, almost half of cases are associated with an inherited syndrome. The highest malignancy rates are seen in paragangliomas (PGs) associated with SDHB mutations, which are usually abdominal and secretory.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Sardo E, Cameselle-Garcia S, Casteras A, Toledo R, Acosta D,

Keywords: Paraganglioma, SDHB mutations, Functioning Tumors,

#2894 Single Institution Experience with Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)

Introduction: Neuroendocrine tumors (NETs) are a rare and heterogenous group of tumors with rising incidence. Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogue is an encouraging systemic treatment modality with minimum side effects.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Duan H

Authors: Duan H, Ninatti G, Girod B, Ferri V, Guja K,

Keywords: NET, PRRT, ORR, PFS,

#2788 Favourable Outcome in Patients with Metastatic Pheochromocytomas and Paragangliomas Treated with 177Lu-DOTATATE

Introduction: There is limited previous data on Peptide receptor radiotherapy (PRRT) in pheochromocytoma (PCC) and paraganglioma (PGL).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Vyakaranam A

Authors: Vyakaranam A, Crona J, Thiis-Evensen E, Hellman P, Norlén O,

Keywords: PRRT, 177Lu-DOTATATE, Pheochromocytoma, Paraganglioma,

#2780 Intracardiac Paragangliomas (PGLs): A Single-Institution Experience

Introduction: Intracardiac PGLs are extremely rare neuroendocrine tumors. There are few reported series in literature, indicating surgery as the most effective treatment modality.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Rossi M, Bora G, Lanza G, Meda S, Olivetti S,

Keywords: Intracardiac paraganglioma,

#1904 Treatment of Paragangliomas with Lutetium-177-Octreotate Based Peptide Receptor Radionuclide Therapy

Introduction: Paragangliomas (PGL) are a heterogeneous group of rare tumours that can express high numbers of somatostatin receptors on their cell surface and can be targeted with peptide receptor radionuclide therapy (PRRT) using the radiolabelled somatostatin analogue [lutetium-177-DOTA-Tyr3-]octreotate (177Lu-octreotate).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Smit Duijzentkunst D

Authors: Smit Duijzentkunst D, Kwekkeboom D,

Keywords: PRRT, paragangliomas,